Clinical Research Directory

Inclusion Criteria: * Histologically or cytology proven non-small cell lung cancer (NSCLC) * NSCLC stage III or IV * ≥ 18 years * ECOG performance status 0- 2 * Eligible patients should have initiated first-line treatment for advanced or metastatic disease with chemotherapy and/or immunotherapy, radiochemotherapy or targeted treatment * Patients are eligible for inclusion if they have responded to first-line treatment with stable disease, or better, at the first radiological evaluation performed up to six months after start of treatment * Stable disease, or better, on radiological assessment within 28 days of enrolment (CT scan or FDG-PET/CT. Cerebral MRI if known brain metastasis) * Initial web-based application score of ≤ 6 * Basic computer literacy * Bank-ID (electronic identification system) and access to "1177 Vårdguiden" * The subject has given written consent to participate in the study Exclusion Criteria: * Symptomatic brain metastases * Pregnancy, breastfeeding, or planned pregnancy * Persons under guardianship or deprived of liberty * Mental inability, reluctance or language difficulties that result in difficulty understanding the meaning of study participation * Treatment or disease which, according to the investigator, can affect treatment or study results * Ongoing participation in another interventional clinical study